Novartis AG (NVS) is a Swiss multinational pharmaceutical company whose American Depositary Receipt (ADR — a U.S.-traded certificate representing foreign shares) is listed on the NYSE. Reviewing eight recent, attributable analyst targets yields a broad spread: HSBC raised its target to $136 (Hold), Goldman Sachs sits at $139 (Sell), Berenberg at $147 (Hold), Morgan Stanley at $156 (Buy, lowered from $170), Argus Research at $170 (Buy), TD Cowen at $180 (Hold), and Bank of America Securities at $185 (Buy). Barclays holds a Swiss-franc target of CHF 125 (roughly $140, Equal Weight).
The overall mean of these targets is about $157 — only about 4% above the current price. Because that fails a meaningful-upside test, the central $170 target used here is calculated only from the four targets above the current price ($185, $180, $170, and $156), whose average is $172.75, rounded to $170. Notably, $170 also happens to be near the stock's prior 52-week high, making it a realistic but contested level rather than a consensus forecast.
At roughly $151.12, the stock trades near the middle of its 52-week range of about $121.57 to $170.46. Reaching $170 would require a gain of about 12.5% — a modest move relative to the stock's historical volatility, but a meaningful one given recent negative news flow. The shares pulled back in October 2026 after Phase III data for remibrutinib in multiple sclerosis came in slightly below expectations on key efficacy measures, prompting Barclays to trim its target. On fundamentals, Novartis has posted mid-to-high single-digit sales growth, guided for continued core operating-income expansion, and trades around a P/E (price-to-earnings ratio) in the low-to-mid 20s with a dividend yield near 3%.
Novartis' growth increasingly rests on newer oncology and immunology medicines — including Kisqali, Pluvicto, Cosentyx, Fabhalta, and Scemblix — and on the anticipated launch of Rhapsido, which Morgan Stanley cited in its upgrade to Overweight. The company is also navigating the loss of exclusivity on Entresto and other blockbusters while expanding in cancer and autoimmune therapies through acquisitions. A return toward $170 would likely require positive data from the RECHARGE study, a successful Rhapsido launch, and continued double-digit growth from key growth drivers.
The near-term picture carries genuine headwinds. Remibrutinib's softer multiple-sclerosis readout, earlier failures for pelacarsen and del-desiran, and generic competition for Entresto all weigh on sentiment. HSBC, which upgraded the stock to Hold in September, still flags a near-term consensus downgrade cycle. Goldman Sachs' Sell rating and sub-$140 target reflect a more cautious view on pipeline execution. Currency is an additional factor, as the ADR is exposed to the Swiss franc. If pipeline setbacks continue or growth decelerates more than expected, the stock could struggle to reclaim its prior high.
The $170 area is a natural resistance level, effectively the stock's 52-week high of about $170.46. Below the current price, the low-$140s acted as a support level in early October 2026, with the 52-week low near $121.57. A sustained move toward $170 would likely require the stock to first hold above $150 and then clear the $156–$160 zone, where several analyst targets cluster.
Most analyst price targets reflect a roughly 12-month research horizon, though firms differ in methodology. Investors should watch the RECHARGE study readout, additional remibrutinib data and regulatory next steps, the Rhapsido launch trajectory, Entresto generic dynamics, quarterly earnings and guidance updates, and Swiss-franc currency movements. Analyst revisions — several firms have already raised or lowered targets this year — will also shape the path toward or away from $170.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, track existing positions, and spot changing trends more efficiently than manual screening allows. For investors following NVS, the tool offers an automated way to complement fundamental research with real-time technical context.
Can Novartis AG (NVS) stock reach $170? The target — the average of the four analyst price targets above the current price — implies a roughly 12.5% advance back to the stock's prior 52-week high. The case for reaching it rests on execution across the oncology and immunology pipeline, a successful Rhapsido launch, and a managed transition through Entresto's generic erosion. The case against rests on recent pipeline disappointments, including remibrutinib, pelacarsen, and del-desiran, as well as a wide analyst range that extends from about $136 to $185. With the overall consensus near $157 sitting only modestly above the price, reaching $170 is plausible but far from assured; upcoming data readouts and earnings updates will be decisive.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.